Long term treatment free remission can be achieved in most chronic myeloid leukaemia patients who show a deep molecular response with second-line nilotinib therapy, researchers from South Australia have shown in a multinational trial. The findings come from a trial led by researchers from South Australian Health and Medical Research Institute, who studied 163 patients ...
Treatment-free remission achieved in CML patients with second-line nilotinib
By Michael Woodhead
23 Feb 2018